Charles River Laboratories International Inc
CRL: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|V& | LOCK|>W | LOCK|KsNW$v% |
Charles River Earnings: Improving Demand Environment Supports Stronger Near-Term Outlook
Charles River reported second-quarter revenue of $1 billion, a decline of 2.7% from the prior year. Management now anticipates 2026 revenue will decline 3% at the midpoint, an improvement from its previous outlook of negative 4.75%.
